InvestorsHub Logo
Post# of 181935
Next 10
Followers 70
Posts 802
Boards Moderated 0
Alias Born 07/24/2010

Re: None

Friday, 09/28/2018 5:09:35 AM

Friday, September 28, 2018 5:09:35 AM

Post# of 181935
An even more possible pharmaceutical partner is Mars Inc.

Mars Inc is a $9.1 billion company and has a Canadian division (that explains the tweet from George Sharp that he went to Toronto)

Mars Inc took over VCA Inc in January 2017

https://www.mars.com/docs/default-source/default-document-library/mars-incorporated-to-acquire-vca-inc.pdf?sfvrsn=0

In RDGL's PR of Sept 2017, RDGL/ADMD was talking about VCA Inc......... that's why I think Mars Inc is a real possibility.

RICHLAND, Wash., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Advanced Medical Isotope Corporation ("AMI") (OTC PINK:ADMD), a late stage radiation oncology focused medical device company’s business plan is to generate initial revenues from animal therapy while pursuing FDA approval to use RadioGel™ for skin cancer in humans. The strategy is to prove the safety and effectiveness of the product via testing at four university veterinary hospitals.

Consolidation in the private veterinary clinic space enables the Company to cost-effectively form business arrangements with the large consortiums of private clinics. We met and had discussions with the Veterinary Cancer Group (VCG) and with VCA Inc. to gain firsthand information on the steps required to market RadioGel™ in the commercial sector. VCG has 55 veterinary centers feeding into three specialty clinics. VCA has 820 clinics in the US and Canada feeding into approximately 25 specialty treatment centers.

Both consortiums confirmed the importance of learning from the testing that we are sponsoring at the university veterinary centers. They encouraged us to publish the results in a scientific journal. VCG was interested in teaming with the universities by conducting some of the testing in their own facilities. They both emphasized the importance of obtaining a written confirmation from the veterinary side of the FDA that RadioGel™ is a device. After the data collection is completed the results will be sent to their internal review boards for approval. The final stage is a business contract to purchase RadioGel™ for use in their clinics.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDGL News